Strikingly, according to the gathered reports, only four Latin American countries (Argentina, Brazil, Colombia and Mexico) conduct the screening of DMD small sequence variants, that is to say, the complete molecular diagnostic algorithm for dystrophinopathies (CNV and SNV). This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin.